Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
Antiasthma Drugs: Methylxanthines01:24

Antiasthma Drugs: Methylxanthines

Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Inhaled Medications01:23

Inhaled Medications

Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Epitope Mapping Using Yeast Display and Next Generation Sequencing.

Methods in molecular biology (Clifton, N.J.)·2018
Same author

Brain-injured Survivors of Monochorionic Twin Pregnancies Complicated by Single Intrauterine Death: MR Findings in a Multicenter Study.

Radiology·2018
Same author

Acute Communicating Hydrocephalus as Spinal Cord Surgery Complication in Patient with Lumbar Lipomyelocele.

World neurosurgery·2018
Same author

Unusual white matter involvement in EAST syndrome associated with novel KCNJ10 mutations.

Journal of neurology·2018
Same author

Role of MRI T2-DRIVE in the assessment of pituitary stalk abnormalities without gadolinium in pituitary diseases.

European journal of endocrinology·2018
Same author

Echocardiographic advances in hypertrophic cardiomyopathy: Three-dimensional and strain imaging echocardiography.

Echocardiography (Mount Kisco, N.Y.)·2018
Same journal

Real-Life Effectiveness of Aclidinium/Formoterol on COPD Control: The REDACT Observational Study.

International journal of chronic obstructive pulmonary disease·2026
Same journal

Effective-Component Compatibility of Bufei Yishen Formula Alleviates Alveolar Epithelial Barrier Damage in COPD Through Inhibition of p38 MAPK Phosphorylation.

International journal of chronic obstructive pulmonary disease·2026
Same journal

Cardiopulmonary Exercise Testing and Quantitative Chest CT in COPD: The Stronger Association of Emphysema Over Airway Thickness with Functional Impairment.

International journal of chronic obstructive pulmonary disease·2026
Same journal

A Nomogram for Predicting Successful Weaning from Invasive Mechanical Ventilation Withdrawal in Patients with Chronic Obstructive Pulmonary Disease Complicated by Respiratory Failure.

International journal of chronic obstructive pulmonary disease·2026
Same journal

Diagnostic Value of miR-192-5p in the Progression of Chronic Obstructive Pulmonary Disease Complicated with Pulmonary Heart Disease.

International journal of chronic obstructive pulmonary disease·2026
Same journal

Association Between Chronic Obstructive Pulmonary Disease and Survival in Patients with Lung Cancer: A Nationwide Cohort Study.

International journal of chronic obstructive pulmonary disease·2026
See all related articles

Related Experiment Video

Updated: May 9, 2026

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

Indacaterol: a comprehensive review.

Andrea Rossi1, Guido Polese

  • 1Pulmonary Unit, Cardiovascular and Thoracic Department, University and General Hospital, Verona, Italy. andrea.rossi2@ospedaleuniverona.it

International Journal of Chronic Obstructive Pulmonary Disease
|August 8, 2013
PubMed
Summary
This summary is machine-generated.

Indacaterol, a once-daily long-acting beta-adrenergic agent (LABA), offers rapid and sustained bronchodilation for chronic obstructive pulmonary disease (COPD) management. It improves lung function, reduces hyperinflation, and enhances patient adherence, representing a significant advancement in COPD treatment.

Keywords:
chronic obstructive pulmonary diseaseindacaterol

More Related Videos

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Methodology for Sputum Induction and Laboratory Processing
13:28

Methodology for Sputum Induction and Laboratory Processing

Published on: December 17, 2017

Related Experiment Videos

Last Updated: May 9, 2026

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Methodology for Sputum Induction and Laboratory Processing
13:28

Methodology for Sputum Induction and Laboratory Processing

Published on: December 17, 2017

Area of Science:

  • Pulmonology
  • Pharmacology

Background:

  • Chronic obstructive pulmonary disease (COPD) is a progressive respiratory condition with no current cure.
  • Existing treatments, including pharmacologic and non-pharmacologic interventions, aim to alleviate symptoms and improve quality of life.
  • A shift towards viewing COPD as a preventable and treatable disease is crucial for effective patient management.

Purpose of the Study:

  • To evaluate indacaterol, a novel once-daily long-acting beta-adrenergic agent (LABA), for the treatment of COPD.
  • To assess the efficacy of indacaterol in improving lung function, reducing pulmonary hyperinflation, and enhancing patient outcomes.
  • To compare indacaterol's effectiveness with other bronchodilators and examine its impact on patient adherence.

Main Methods:

  • Review of dose-finding trials and clinical studies investigating indacaterol's pharmacokinetic and pharmacodynamic properties.
  • Assessment of indacaterol's onset and duration of action compared to salbutamol, salmeterol, and formoterol.
  • Evaluation of indacaterol's effects on lung volumes, exercise tolerance, and daily activities in COPD patients across different disease stages.

Main Results:

  • Indacaterol provides rapid bronchodilation (within five minutes) and sustained 24-hour effect, acting as a 'pharmacologic stent' to reduce lung hyperinflation.
  • Once-daily administration of indacaterol significantly improves patient adherence to therapy.
  • Doses of 150 μg and 300 μg indacaterol demonstrate superior efficacy in improving lung function and patient-oriented outcomes compared to other bronchodilators, particularly in patients with moderate airflow obstruction.

Conclusions:

  • Indacaterol represents a significant advancement in COPD management, offering rapid and long-lasting bronchodilation with improved patient adherence.
  • The 150 μg and 300 μg doses are particularly effective in reducing pulmonary hyperinflation and improving exercise capacity.
  • Indacaterol exhibits a favorable safety profile and is well-tolerated across all stages of COPD, warranting further research in moderate airflow obstruction.